The U.S. Food and Drug Administration granted accelerated approval to lecanemab, marketed as Leqembi, on January 6, 2023, based on the surrogate endpoint of amyloid plaque reduction observed in a Phase 2 trial. Now, the agency faces a critical decision on traditional, or full, approval for the Alzheimer’s drug, with a target date of July 6, 2023, under the Prescription Drug User Fee Act, commonly referred to as the PDUFA date.
Concurrently, the Centers for Medicare & Medicaid Services is reconsidering its national coverage determination for anti-amyloid antibodies, a policy that currently restricts coverage to patients enrolled in clinical trials and has been a barrier to widespread adoption.
Regulatory Path and Advisory Committee Recommendation
The FDA’s accelerated approval pathway was created to allow earlier access to therapies when conditions lack effective treatments, and lecanemab qualified for this route based on its impact on amyloid plaque, a surrogate endpoint considered reasonably likely to predict clinical benefit. In June 2023, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously, 6-0, to recommend traditional approval. The committee cited confirmatory results from the Clarity AD Phase 3 trial, which showed cognitive benefit for patients receiving lecanemab.
This unanimous vote carries weight as a signal to the agency, though the final decision rests with the FDA itself. The agency operates as the federal unit within the U.S. Department of Health and Human Services, overseeing food safety, drug approval, and a broad range of consumer and medical products under the Federal Food, Drug, and Cosmetic Act and related statutes.
Its decisions are informed by advisory committees and a commissioner appointed by the president, and they set precedent for later drug reviews and influence Medicare coverage standards.
Medicare Coverage Reconsideration and Patient Access
On June 1, 2023, CMS announced it would reconsider its national coverage determination for anti-amyloid antibodies, the class of drugs that includes lecanemab. The current policy limits coverage to patients enrolled in clinical trials, a restriction that has constrained patient access despite the drug’s accelerated approval. CMS Administrator Chiquita Brooks-LaSure stated that a revised coverage decision would be issued after the FDA’s traditional approval.
If the FDA grants full approval, Medicare coverage would likely expand, though it could require a registry to track patient outcomes. The Alzheimer’s Association has urged CMS to provide broad coverage without restrictions, citing the unmet need for treatments that can slow the progression of the disease.
The agency’s reconsideration signals a potential shift in patient access, as Medicare coverage is a pivotal factor in the commercial viability of Alzheimer’s therapies. Beyond lecanemab, these decisions will shape the competitive landscape for other anti-amyloid antibodies currently in development, including donanemab and remternetug, both from Eli Lilly and in Phase 3 trials.
Global Implications and Market Context
The Alzheimer’s treatment market represents a substantial commercial opportunity, and lecanemab’s regulatory path extends beyond U.S. borders. The European Medicines Agency is reviewing lecanemab, with a decision expected in late 2023. Eisai, the drug’s developer, has also submitted applications in Japan, China, and other countries. These regulatory decisions will determine patient access across multiple continents and the drug’s commercial viability worldwide.
The outcomes also affect future Alzheimer’s therapies in development; the FDA’s approval pathway and subsequent CMS coverage determinations will set a precedent for drugs like donanemab and remternetug, both in Phase 3 trials. The CMS reconsideration of its national coverage determination marks a potential shift in how patients access anti-amyloid antibodies.
The immediate catalysts in the coming weeks include the FDA’s decision on traditional approval by July 6, 2023, followed by a revised CMS coverage determination. The EMA’s ruling in late 2023 will determine European access. For readers, these agency choices affect access to new treatments and the standards behind them.
Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “FDA’s critical decision looms on full approval for Alzheimer’s drug”, “description”: “WASHINGTON, July 14 — The U.S. Food and Drug Administration granted accelerated approval to lecanemab, marketed as Leqembi, on January 6, 2023, based on the…”, “datePublished”: “2026-07-14T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Henry Thomas”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
